Estrogen Receptor in Human Breast Cancer in Relation to Tumor Morphology and Endocrine Therapy

Paszko, Z; Padzik, H; Dabska, M; Pieńkowska, F

doi:10.1177/030089167806400507

Cited by 8 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ER is expressed in the majority of breast tumours (Jonat and Maass, 1978; Lee and Markland, 1978; Paszko et al , 1978) and in a number of endocrine tissues including the normal breast, uterus and vagina, as well as in the pituitary and hypothalamus.…”

Section: Oestrogen Signalling As a Target For Breast Cancer Therapymentioning

confidence: 99%

Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action

2004

View full text Add to dashboard Cite

Due to their favourable tolerability profiles, endocrine therapies have long been considered the treatment of choice for hormone-sensitive metastatic breast cancer. However, the oestrogen agonist effects of the available selective oestrogen receptor modulators, such as tamoxifen, and the development of cross-resistance between endocrine therapies with similar modes of action have led to the need for new treatments that act through different mechanisms. Fulvestrant (‘Faslodex’) is the first of a new type of endocrine treatment – an oestrogen receptor (ER) antagonist that downregulates the ER and has no agonist effects. This article provides an overview of the current understanding of ER signalling and illustrates the unique mode of action of fulvestrant. Preclinical and clinical study data are presented in support of the novel mechanism of action of this new type of ER antagonist.

show abstract

Section: Oestrogen Signalling As a Target For Breast Cancer Therapymentioning

confidence: 99%

Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action

2004

View full text Add to dashboard Cite

show abstract

Hormone receptor levels related to histological parameters of tumor‐host relationships in female breast carcinoma

Syrjänen

Kosma²

1982

Journal of Surgical Oncology

View full text Add to dashboard Cite

A series of 115 female breast carcinomas was studied with special emphasis on the relationships between the hormone receptor (ER and PR) levels and the histological parameters reflecting tumor-host reactivity. Carcinomas were classified according to their nuclear grade (NC) and the stromal host reactions; perivenous lymphocyte infiltration (PVI), lymphocyte (LD), plasma cell (PCI), and mast cell infiltration (MI) were assessed. NG did correlate directly with the ER positivity, but not with the absolute ER values. LI and PCI, but not MI and PVI, showed an inverse relation to the ER values, but not to those of PR. ER and to lesser extent the PR values were higher in postmenopausal than in premenopausal women. The findings are discussed in the light of tumor-host relationships, and conclusion is drawn that the receptor determinations used in connection with the histological evaluation of these parameters (NG especially) are of definite benefit in dividing the breast cancer patients into groups of different expectancy of the future outcome of their disease.

show abstract